<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50143">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453425</url>
  </required_header>
  <id_info>
    <org_study_id>Sepsis-studien</org_study_id>
    <nct_id>NCT02453425</nct_id>
  </id_info>
  <brief_title>The Effects of Blood Pressure on Renal Function and Oxygenation in Septic Shock</brief_title>
  <official_title>Goal Directed Therapy in Septic Shock - the Effects of Mean Arterial Pressure Levels, Adjusted With Norepinephrine, on Renal Perfusion, Function and Oxygenation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate renal effects of 3 different levels of mean
      arterial pressure in early case of septic shock. In 8 patients diagnosed with early septic
      shock, we will adjust mean arterial pressure (MAP) to three different levels, using
      norepinephrine. At each level of MAP, central and renal hemodynamics and oxygenation states
      will be measured. Analysis will be made to evaluate at which MAP renal function and
      oxygenation is least affected negatively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is under debate what level of mean arterial pressure is the most appropriate for organ
      perfusion in septic shock. The kidneys are usually used for end-organ evaluation of
      appropriate perfusion and appropriate blood pressure level. What &quot;adequate blood pressure&quot;
      means is today unclear, and this is what we will evaluate in this study:

      The purpose of this study is to evaluate renal effects of 3 different levels of mean
      arterial pressure in early phase of septic shock.

      Patients will be included within the first 24 hrs after admission to the ICU diagnosed with
      septic shock. They must be sedated, mechanically ventilated and in need for norepinephrine
      for adequate blood pressure levels.

      After 60 mins of steady state at MAP 75 mmHg, norepinephrine will be adjusted achieve MAP of
      60 and 90 mmHg respectively, MAP being held at each level for 30 mins. At the end of each 30
      mins period, central and renal hemodynamics will be measured, blood and urine samples will
      be collected.

      Central hemodynamics will be measured by, and blood samples collected via a pulmonary
      catheter and an arterial line.

      Renal hemodynamics will be measured using a renal vein catheter for retrograde
      thermodilution giving at hand renal blood flow (RBF), renal vein blood samples and urine
      collection provides extraction of Cr-EDTA for filtration fraction (FF) and glomerular
      filtration rate (GFR), renal oxygen consumption, and renal oxygen extraction as a measure of
      balance between renal oxygen delivery and consumption.

      Via renal vein catheterisation and retrograde thermodilution, we have the unique possibility
      to actually evaluate renal blood flow, renal oxygenation and renal function in humans in
      vivo.

      After finishing the data collection, analysis will be made to answer the question: which MAP
      is the most optimal concerning RBF, GFR and renal oxygenation in patients with septic shock?
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>195 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Blood Flow (RBF)</measure>
    <time_frame>195 mins</time_frame>
    <description>ml/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Oxygen consumption</measure>
    <time_frame>195 mins</time_frame>
    <description>ml/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Filtration fraction</measure>
    <time_frame>195 mins</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal oxygen supply/demand relationship</measure>
    <time_frame>195 min</time_frame>
    <description>Renal oxygen consumption compared to renal oxygen delivery (CaO2-CrvO2/CaO2).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Septic Shock</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>60 mmHg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norepinephrine adjusted to reach MAP 60 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 mmHg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norepinephrine adjusted to reach MAP 75 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mmHg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norepinephrine adjusted to reach MAP 90 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MAP 60 mmHg</intervention_name>
    <description>Norepinephrine adjusted to reach MAP 60 mmHg</description>
    <arm_group_label>60 mmHg</arm_group_label>
    <other_name>Norepinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MAP 75 mmHg</intervention_name>
    <description>Norepinephrine adjusted to reach MAP 75 mmHg</description>
    <arm_group_label>75 mmHg</arm_group_label>
    <other_name>Norepinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MAP 90 mmHg</intervention_name>
    <description>Norepinephrine adjusted to reach MAP 90 mmHg</description>
    <arm_group_label>90 mmHg</arm_group_label>
    <other_name>Norepinephrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stable septic shock

          -  normovolemic

          -  norepinephrine

          -  intubated/ventilated

          -  normal s-creatinine according to local laboratory regards.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven-Erik Ricksten, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenny Skytte Larsson, MD</last_name>
    <phone>0046706964800</phone>
    <email>jenny.skytte@vgregion.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital, dpt of anesthesiology and intensive care</name>
      <address>
        <city>GÃ¶teborg</city>
        <state>VGR</state>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Skytte Larsson, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 20, 2015</lastchanged_date>
  <firstreceived_date>April 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Jenny Skytte Larsson</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>renal blood flow</keyword>
  <keyword>renal oxygenation</keyword>
  <keyword>glomerular filtration rate</keyword>
  <keyword>filtration fraction</keyword>
  <keyword>blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
